Renal patients are among the most challenging to manage due to multiple co-morbidities and poor outcomes. Nephrologists see a wide array of patients including those across all five stages of chronic kidney disease, those on dialysis and those with kidney transplants. At Spherix, we have an intimate understanding of the US dialysis market, unparalleled perspective on hospital-based nephrology practice and a unique glimpse into the patient flow within private practice nephrology.
Our independent reports and acumen can be leveraged to help:
-Understand the degree of unmet need and align business development opportunities
-Closely monitor the subtle shifts in the established markets for renal anemia and CKD-MBD as well as the evolving market for hyperkalemia
-Understand how nephrology practice is evolving and how the payment systems themselves impact these shifts
-Understand the current treatment approaches for an array of conditions such as diabetic nephropathy, lupus nephritis and acute kidney injury and how the paradigm will shift in the near-term future
-Understand the role of ancillary healthcare professionals (nurse practitioners, renal dietitians) and patients themselves in the care continuum.
Direct from our Research!
March 17. AstraZeneca received a second Complete Response Letter for ZS-9, delaying approval yet again and leaving a wide-open runway for Veltassa.
There is a sharp divide between nephrologists and cardiologists when it comes to the use of Veltassa. Cardiologists tend to be more conservative in their management, intervening at lower elevations of serum potassium compared to their nephrology colleagues. Even with earlier intervention for hyperkalemia, Veltassa trial rates significantly lag those of nephrologists.